These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

771 related articles for article (PubMed ID: 11057120)

  • 1. [HMG-CoA reductase inhibitors in prevention of cardiovascular diseases: new mechanisms, aspects and trials].
    Wojakowski W; Gmiński J
    Przegl Lek; 2000; 57(5):291-5. PubMed ID: 11057120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Anti-atherosclerotic actions of HMG-CoA reductase inhibitors].
    Gmiński J; Wojakowski W
    Przegl Lek; 1997; 54(11):782-7. PubMed ID: 9501689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacotherapy of arteriosclerosis and its complications. Effect of ACE inhibitors and HMG-CoA-reductase inhibitors].
    Tschudi MR; Noll G; Lüscher TP
    Schweiz Med Wochenschr; 1997 Apr; 127(15):636-49. PubMed ID: 9198890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient.
    Ong HT
    QJM; 2005 Aug; 98(8):599-614. PubMed ID: 16006501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protecting the heart: a practical review of the statin studies.
    Ong HT
    MedGenMed; 2002 Dec; 4(4):1. PubMed ID: 12817199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pleiotropic effects of HMG-CoA reductase inhibitors.
    Bocan TM
    Curr Opin Investig Drugs; 2002 Sep; 3(9):1312-7. PubMed ID: 12498006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Basic science review: Statin therapy--Part I: The pleiotropic effects of statins in cardiovascular disease.
    Sadowitz B; Maier KG; Gahtan V
    Vasc Endovascular Surg; 2010 May; 44(4):241-51. PubMed ID: 20403949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?
    März W; Köenig W
    J Cardiovasc Risk; 2003 Jun; 10(3):169-79. PubMed ID: 12775949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesterol 2001. Rationale for lipid-lowering in older patients with or without CAD.
    Aronow WS
    Geriatrics; 2001 Sep; 56(9):22-5, 28-30. PubMed ID: 11582971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Statins with a perspective of lifelong therapy].
    Ertaş FS
    Turk Kardiyol Dern Ars; 2009 Mar; 37 Suppl 2():29-36. PubMed ID: 19404048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What role for [black triangle down] colesevelam in cardiovascular prevention?
    Drug Ther Bull; 2009 May; 47(5):53-5. PubMed ID: 19423677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
    Daskalopoulou SS; Mikhailidis DP
    Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Statins: possibly more than just lowering of the lipid level].
    Visseren FL; Lansberg PJ; Erkelens DW; Kastelein JJ
    Ned Tijdschr Geneeskd; 2000 Feb; 144(7):316-21. PubMed ID: 10707742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statins in hypertension: are they a new class of antihypertensive agents?
    Feldstein CA
    Am J Ther; 2010; 17(3):255-62. PubMed ID: 19918164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
    Hennekens CH; Schneider WR
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacological effects of HMG-CoA reductase inhibitors].
    Tomita N; Morishita R; Ogihara T
    Nihon Rinsho; 2002 May; 60(5):955-61. PubMed ID: 12029999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Advances in cholesterol-lowering interventions].
    Ascaso JF
    Endocrinol Nutr; 2010 May; 57(5):210-9. PubMed ID: 20451478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.